Human Factor XIa

<strong>Human Factor XIa</strong>_x000D_ <strong>Catalog number:</strong> B2014056_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 0.1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 160 kDa_x000D_ <strong>Supplied as:</strong> N/A_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Human Factor XIa_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Perera V, Wang Z, Luettgen J, Li D, DeSouza M, Cerra M, Seiffert D. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor Clin Transl Sci. 2022 Feb;15(2):330-342._x000D_ 2: Heitmeier S, Visser M, Tersteegen A, Dietze-Torres J, Glunz J, Gerdes C, Laux V, Stampfuss J, Roehrig S. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa J Thromb Haemost. 2022 Jun;20(6):1400-1411._x000D_ 3: Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, James SK, Jones WS, Merkely B, Keller L, Hermanides RS, Campo G, Ferreiro JL, Shibasaki T, Mundl H, Alexander JH; PACIFIC AMI Investigators. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction Circulation. 2022 Oct 18;146(16):1196-1206._x000D_ 4: Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, Agafina A, Campbell B, Caso V, Mas JL, Dong Q, Turcani P, Christensen H, Ferro JM, Veltkamp R, Mikulik R, De Marchis GM, Robinson T, Lemmens R, Stepien A, Greisenegger S, Roine R, Csiba L, Khatri P, Coutinho J, Lindgren AG, Demchuk AM, Colorado P, Kirsch B, Neumann C, Heenan L, Xu L, Connolly SJ, Hart RG; PACIFIC-Stroke Investigators. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial Lancet. 2022 Sep 24;400(10357):997-1007._x000D_ 5: Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, Mahaffey KW, Notani RS, Roberts R, Segers A, Raskob GE; AXIOMATIC-TKR Investigators. Milvexian for the Prevention of Venous Thromboembolism N Engl J Med. 2021 Dec 2;385(23):2161-2172._x000D_ 6: Yi BA, Freedholm D, Widener N, Wang X, Simard E, Cullen C, Al-Saady NM, Lepor NE, Coulter S, Lovern M, Bloomfield D. Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa J Thromb Haemost. 2022 Feb;20(2):307-315._x000D_ 7: Kar S, Mottamal M, Al-Horani RA. Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia ChemistryOpen. 2020 Nov 10;9(11):1161-1172._x000D_ 8: Loukas A, Hotez PJ, Diemert D, Yazdanbakhsh M, McCarthy JS, Correa-Oliveira R, Croese J, Bethony JM. Hookworm infection Nat Rev Dis Primers. 2016 Dec 8;2:16088._x000D_ 9: Al-Horani RA, Parsaeian E, Mohammad M, Mottamal M. Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies Chem Biol Drug Des. 2022 Jul;100(1):64-79._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/34577586">10: Kar S, Bankston P, Afosah DK, Al-Horani RA. Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor XIa Pharmaceuticals (Basel). 2021 Aug 31;14(9):886. </a>_x000D_ _x000D_ <strong>Products Related to Human Factor XIa can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>